Navigation Links
AngelMD Investor Group Closes Second Round of Funding in Noninvasix
Date:1/8/2019

Today AngelMD announced that it completed a syndicate investment comprised of its members into Noninvasix. This represents the second investment AngelMD has made into Noninvasix in the past year.

To reduce the incidence of neonatal mortality and morbidity, Noninvasix is developing a patient monitor to directly, accurately, and noninvasively measure brain oxygenation in preterm babies in the NICU. Early detection of inadequate brain oxygenation will allow neonatologists to intervene before cerebral function is permanently compromised.

Leading the AngelMD syndicate of investors was Jagjit Khairah, DO, FACOG, Department of Obstetrics & Gynecology, Kelsey Seybold Clinic who had this to say about Noninvasix: “The technological advances used with by Noninvasix to detect levels of oxygenation without needing a blood sample is remarkable. To have instant results using acoustic and laser sensor related probes will enable health care teams across many specialties of medicine to expedite critical care. Graham and his team have an amazing vision and are poised to help us change the way we address the needs of our patients on many fronts using this innovative technology.”

“Raising money through AngelMD is basically raising money from our future users. These are the people who understand best how Noninvasix’s technology can be a solution to some of their biggest issues.” said Graham Randall, CEO Noninvasix. “While we value all capital investment, having a group of engaged and supportive physicians backing us brings value well beyond the money.”

About Noninvasix

Noninvasix is developing non-invasive precision oximetry, which will allow doctors for the first time to accurately monitor oxygen sufficiency within organs without invasive catheters. Inadequate organ oxygenation is a major cause of death and permanent disability in hospitals. Prompt recognition of low venous oxygenation can be used to guide therapeutic interventions and reduce adverse outcomes.

With patented optoacoustic technology at its core, Noninvasix’s system consists of a disposable probe that can be worn on the head, chest or wrist — depending on the desired metric — and a display console.

Noninvasix's undertaking is backed by 15 years of optoacoustic research by its co-founders, more than $6.5 million in research grants, 9 patents, and validation in peer-review journal articles.

For more information, visit http://noninvasix.com/

About AngelMD

AngelMD, an online Healthcare Investment and Innovation Marketplace, connects and engages a network of physicians, angel investors, early stage healthcare companies and subject matter experts through a powerful technology platform to create better outcomes for patients and investors. For more information, visit http://www.angelmd.co

Read the full story at https://www.prweb.com/releases/angelmd_investor_group_closes_second_round_of_funding_in_noninvasix/prweb16018138.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. angelMD Completes Investment in Bleeding Detection Medical Device Company
2. 3 angelMD Startups Make Livestrong Big C Semi-finals
3. Brainstorm Cell Therapeutics to Present at ARMs 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston
4. Audentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
5. Viking Therapeutics to Present at H.C. Wainwright & Co.s 1st Annual NASH Investor Conference
6. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
7. NW Bio Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors
8. Capricor Therapeutics to Present at Two Investor Conferences in March
9. Relmada Therapeutics to Participate in BIO CEO and Investor Conference
10. Biotech Stocks on Investors Radar -- Amicus Therapeutics, Cempra, Ophthotech, and Sarepta Therapeutics
11. Arcturus Therapeutics to Present at the 19th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2019)... California (PRWEB) , ... May ... ... of our patent applications from the USPTO providing proprietary interest to our ... METHOD FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including ...
(Date:5/22/2019)... ... May 22, 2019 , ... Artemis (formerly Agrilyst), the leading ... A funding round co-led by Astanor Ventures and Talis Capital ... and iSelect Fund . The company has raised $11.75m to date and will ...
(Date:5/14/2019)... ... May 13, 2019 , ... Leak Detection Associates ... the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ is excited to announce ... to improve LDA’s ability to communicate directly with the marketplace; serving as a ...
(Date:5/4/2019)... ... May 03, 2019 , ... More than three thousand people ... the scientist and ufologist Urandir Fernandes de Oliveira, last Thursday (25), during the ... of some research carried out by the association, in partnership with scientists from ...
Breaking Biology Technology:
(Date:6/11/2019)... (PRWEB) , ... June 12, 2019 , ... ... of antibody discovery services, Abveris plans to leverage the Geneious Biologics platform as ... Colby Souders, Chief Technology Officer at Abveris, says: “The Geneious team has done ...
(Date:6/6/2019)... ... June 05, 2019 , ... MedTech ... the global health and medical technology market, announced that it has selected Medacta ... Robotics Solution” award in the 2019 MedTech Breakthrough Awards program. , ...
(Date:6/6/2019)... ... 05, 2019 , ... Ziegler, a specialty investment bank, is ... Laboratories (PBM) on its recent acquisition by PathGroup. , Headquartered in Lewisville ... more than one dozen hospitals and surgery centers in the Dallas-Fort Worth and ...
Breaking Biology News(10 mins):